SEC 13F Intelligence

Managers / Q4 2020 · view latest →

Octagon Capital Advisors LP

CIK 0001839435 · 654 MADISON AVENUE, 21ST FLOOR, NEW YORK, NY, 10065 · 212-369-2829

Reported Value
$288M
Q4 2020
Positions
31
Filings on Record
23
2019–present window
Filed
Feb 16, 2021
original filing

Summary

Octagon Capital Advisors LP reported $288M in U.S.-listed holdings across 31 positions for Q4 2020.

Its largest position, Apellis Pharmaceuticals, represents 10.9% of the portfolio.

Portfolio Metrics

Top-10 Concentration
+61.9%
share of reported value
Largest Position
+10.9%
Apellis Pharmaceuticals

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $288MQ4 ’20Q1 ’21: $265MQ2 ’21: $483MQ3 ’21: $406MQ3 ’21Q4 ’21: $514MQ1 ’22: $463MQ2 ’22: $375MQ2 ’22Q3 ’22: $579MQ4 ’22: $642MQ1 ’23: $695MQ1 ’23Q2 ’23: $719MQ3 ’23: $651MQ4 ’23: $625MQ4 ’23Q1 ’24: $834MQ2 ’24: $636MQ3 ’24: $643MQ3 ’24Q4 ’24: $608MQ1 ’25: $517MQ2 ’25: $456MQ2 ’25Q3 ’25: $660MQ4 ’25: $824MQ1 ’26: $904MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 78.5%Other: 13.0%ADR: 8.4%
  • Common Stock · 78.5% · $227M
  • Other · 13.0% · $38M
  • ADR · 8.4% · $24M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
APELLIS PHARMACEUTICALS INCNEW+548.4K548.4K+$31M$31M
NBPI MABNEW+454.6K454.6K+$21M$21M
CLDXCELLDEX THERAPEUTICS INC NEWNEW+1.04M1.04M+$18M$18M
CURIS INCNEW+2.20M2.20M+$18M$18M
FDMT4D MOLECULAR THERAPEUTICS INNEW+377.8K377.8K+$16M$16M
PMVPPMV PHARMACEUTICALS INCNEW+250.0K250.0K+$15M$15M
ARVNARVINAS INCNEW+178.5K178.5K+$15M$15M
GOSSGOSSAMER BIO INCNEW+1.56M1.56M+$15M$15M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

31 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1APELLIS PHARMACEUTICALS INCCOM10.87%$31M548.4K
2NBPI MABhistory →SPONSORED ADS7.43%$21M454.6K
3CLDXCELLDEX THERAPEUTICS INC NEWhistory →COM NEW6.32%$18M1.04M
4CURIS INCCOM NEW6.25%$18M2.20M
5FDMT4D MOLECULAR THERAPEUTICS INhistory →COM5.43%$16M377.8K
6PMVPPMV PHARMACEUTICALS INChistory →COM5.33%$15M250.0K
7ARVNARVINAS INChistory →COM5.26%$15M178.5K
8GOSSGOSSAMER BIO INChistory →COM5.24%$15M1.56M
9XLRNACCELERON PHARMA INChistory →COM4.98%$14M112.4K
10CHEMOCENTRYX INCCOM4.83%$14M225.1K
11CRDFCARDIFF ONCOLOGY INChistory →COM4.05%$12M650.0K
12AVIDITY BIOSCIENCES INCCOM3.80%$11M430.0K
13DYNDYNE THERAPEUTICS INChistory →COM3.51%$10M481.5K
14TSHATAYSHA GENE THERAPIES INChistory →COM SHS2.95%$9M320.4K
15RCUSARCUS BIOSCIENCES INChistory →COM2.70%$8M300.0K
16CALLIDITAS THERAPEUTICS ABSPONSERED ADS2.33%$7M200.0K
17FIBROGEN INCCOM1.88%$5M146.0K
18KINIKSA PHARMACEUTICALS LTDCOM CL A1.81%$5M295.2K
19RVMDREVOLUTION MEDICINES INChistory →COM1.73%$5M126.1K
20KURAKURA ONCOLOGY INChistory →COM1.70%$5M150.0K
21IVERIC BIO INCCOM1.63%$5M680.0K
22HELIX ACQUISITION CORPCOM CL A1.58%$5M400.0K
23KRONOS BIO INCCOM1.51%$4M146.2K
24JIYA ACQUISITION CORPCOM CL A1.07%$3M300.0K
25VIEVIELA BIO INChistory →COM1.06%$3M85.4K
26IVAINVENTIVA SAhistory →ADS1.01%$3M200.0K
27ARQTARCUTIS BIOTHERAPEUTICS INCCOM0.98%$3M100.0K
28NGM BIOPHARMACEUTICALS INCCOM0.79%$2M75.2K
29ACRSACLARIS THERAPEUTICS INCCOM0.79%$2M350.0K
30KDMNKADMON HLDGS INCCOM0.62%$2M434.1K
31AXSMAXSOME THERAPEUTICS INCCOM0.56%$2M20.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$904M29May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$824M27Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$660M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$456M30Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$517M35May 16, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$608M33Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$643M42Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$636M47Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$834M57May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$625M33Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$651M40Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$719M41Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$695M36May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$642M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$579M35Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$375M20Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$463M24May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$514M28Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$406M30Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$483M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$265M28May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$288M31Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.